60075-23-2

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Dimethoxyphenylacetic acid hydrazide is used as a precursor in the synthesis of various pharmaceutical compounds, particularly for the development of anti-tuberculosis drugs. Its potential in this application is attributed to its ability to be modified and incorporated into drug molecules that target Mycobacterium tuberculosis, the causative agent of tuberculosis.
Used in Antibacterial Applications:
In the field of microbiology, 3,4-Dimethoxyphenylacetic acid hydrazide is used as an antibacterial agent. Its chemical structure allows it to interact with bacterial cells, inhibiting their growth and potentially leading to their destruction. This property makes it a candidate for the development of new antibiotics to combat resistant bacterial strains.
Used in Antifungal Applications:
3,4-Dimethoxyphenylacetic acid hydrazide also exhibits antifungal properties, making it useful in the development of antifungal agents. Its ability to disrupt fungal cell growth and reproduction can be leveraged to create treatments for various fungal infections.
Used in Agriculture:
In the agricultural sector, 3,4-Dimethoxyphenylacetic acid hydrazide is used as a reagent in the synthesis of agrochemicals, including pesticides and fungicides. Its role in this industry is to contribute to the development of more effective and safer products for crop protection.
Used in Materials Science:
3,4-Dimethoxyphenylacetic acid hydrazide has been investigated for its potential use as a corrosion inhibitor in metal surfaces. Its ability to form protective layers on metal surfaces can help prevent corrosion, making it a valuable component in the development of corrosion-resistant coatings and materials.

InChI:InChI=1/C10H14N2O3/c1-14-8-4-3-7(5-9(8)15-2)6-10(13)12-11/h3-5H,6,11H2,1-2H3,(H,12,13)

Upstream product

• 18066-68-7 ethyl 3,4-dimethoxyphenylacetate 
• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 
• 10313-60-7 3,4-dimethoxyphenylacetyl chloride 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Downstream Products

• 385366-49-4 (3,4-dimethoxy-phenyl)-acetic acid N'-(4-phenyl-4,5,6,7-tetrahydro-3H-[1,4]diazepin-2-yl)-hydrazide 
• 436155-42-9 methyl 2-[2-(3,4-dimethoxyphenyl)acetyl]hydrazinecarboxylate 
• 134744-90-4 1-Cyclohexylamino-3-[5-(3,4-dimethoxy-benzyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propan-2-ol 
• 134744-81-3 N-(2,6-Dichloro-phenyl)-2-[5-(3,4-dimethoxy-benzyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide 
• 134744-98-2 1-[5-(3,4-Dimethoxy-benzyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-3-(4-phenyl-piperazin-1-yl)-propan-2-ol 
• 134744-72-2 2-[5-(3,4-Dimethoxy-benzyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-(4-phenyl-piperazin-1-yl)-ethanone 
• 1030015-39-4 C-[5-(3,4-dimethoxy-benzyl)-2H-[1,2,4]triazol-3-yl]-methylamine 
• 891069-94-6 4-ethyl-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 
• 891597-34-5 4-(2-fluorophenyl)-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 
• 891655-90-6 4-(4-methoxyphenyl)-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 
• 883019-31-6 4-(4-fluorophenyl)-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 
• 894238-68-7 4-butyl-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 
• 891586-03-1 4-(4-tolyl)-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 
• 717849-68-8 4-cyclohexyl-1-(3,4-dimethoxyphenylacetyl)thiosemicarbazide 

Relevant academic research and scientific papers

Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator

To explore novel cardiac myosin activator, a series of diphenylalkyl substituted 1,3,4-oxadiazoles and 1,2,4-oxadiazoles have been prepared and tested for cardiac myosin ATPase activation in vitro. In all cases, three carbon spacer between the oxadiazole core and one of the phenyl ring was considered crucial. In case of 1,3,4-oxadiazole, zero to two carbon spacer between oxadiazole core and other phenyl ring are favorable. Phenyl ring can be replaced by cyclohexyl moiety. In case of 1,2,4-oxadiazole, zero or one carbon spacer between the oxadiazole and other phenyl ring are favorable. Introduction of hydrogen bonding donor (NH) group at the 2nd position of the 1,3,4-oxadiazole enhances the activity. Substitutions on either of the phenyl rings or change of phenyl ring to other heterocycle are not tolerated for both the oxadiazoles. The prepared oxadiazoles showed selective activation for cardiac muscle over smooth and skeleton muscles.

Novel triazole derivative with anti-inflammatory and anti-hyperglycemic activity and method for preparing the same

The present invention relates to a novel triazole derivative having anti-inflammatory and anti-diabetic activities, to a production method thereof, and to a pharmaceutical composition for preventing or treating inflammatory diseases and diabetic diseases, comprising the same. The novel triazole derivative according to the present invention has excellent inhibitory activity of type II collagen and COX-2 and exhibits anti-inflammatory activity, and thus can be used as a pharmaceutical composition for the preventing or treating inflammatory diseases. In addition, anti-diabetic activity is showed due to excellent inhibitory activities of alpha-glucosidase and alpha-amylase, thereby being able to be used as a pharmaceutical composition for preventing or treating diabetes diseases.COPYRIGHT KIPO 2017

Synthesis, crystal structure, anti-inflammatory and anti-hyperglycemic activities of novel 3,4-disubstituted 1,2,4-triazol-5(4H)-one derivatives

A new series of 3,4-disubstituted 1,2,4-triazol-5(4H)-one 5a-r, bearing various methoxyphenyl, fluorophenyl, tolyl and phenyl groups, was synthesized by the dehydrocyclization of hydrazinecarboxamides 4a-r by refluxing in a 2 N sodium hydroxide solution. Hydrazinecarboxamides 4a-r was synthesized via the condensation of the corresponding aralkanoic acid hydrazides, 3a-g, with fluoro-, tolyl- and methoxyphenylisocyanates. The newly synthesized compounds (5ar) were characterized by IR, 1H NMR and 13C NMR analyses. The structure of one compound 5a was determined by single crystal X-ray diffraction analysis. All of the synthesized compounds were screened for their anti-inflammatory and anti-diabetic (α-glucosidase and α-amylase inhibition) activity to identify new drugs that might be useful in preventing damage related to diabetes and inflammation. Compounds 5j, 5k and 5m decrease the expression of type II collagen in a dose dependent manner; similarly 5l decrease the COX-2 expression of rabbit articular chondrocytes in a dose dependent manner possessing potent anti-inflammatory potential while some of derivatives including 5c, 5e, 5g and 5h cause inflammation. Meanwhile, excellent α-glucosidase and moderate α-amylase inhibitory profiles against carbohydrate modulating enzymes were demonstrated by compounds 5b, 5f, 5k and 5q compared to the reference standard acarbose, and compounds 5g, 5h, 5i, 5j, 5l and 5o exhibited moderate to low enzyme inhibition potential among the series.

Synthesis, lipophilicity and antimicrobial activity of new derivatives of thiosemicarbazides and 1,2,4-triazoline-5-thione

In the reaction of hydrazide of 3,4-dimethoxyphenylacetic acid (1) with isothiocyanate the respective thiosemicarbazide derivatives (2) were obtained. Further cyclization with 2% NaOH led to the formation of 3- [(3,4- dimethoxyphenyl)methyl]-4-substituted-1,2,4-triazoline-5-thiones (3). The structures of all new products were confirmed by analytical and spectroscopic methods. All compounds were screened for their in vitro activity against some species of aerobic bacteria and fungi. The lipophilicity of the synthesized molecules was also studied.

Intramolecular addition of acyldiazenecarboxylates onto double bonds in the synthesis of heterocycles

Appropriate aryl-substituted unsymmetrical azodicarbonyl compounds, generated from bishydrazides by oxidation, undergo intramolecular cyclisations to furnish a variety of useful heterocycles such as N-substituted oxindoles, carbostyrils, benzazepinones, benzazocinones, benzimidazolones, benzoxazinones and pyrazolones in varying degrees of efficiency. Methods are described to remove the N-acyl groups from the heteroaromatic compounds. Under mildly acidic conditions where equal opportunities are available for an ipso or a normal cyclisation it is the former process that occurs preferentially. Evidence is presented in favour of a C-to-C migration in the ipso product for the formation of a methoxy-substituted carbostyril derivative. One of the spiro substances is shown to participate in dienone-phenol rearrangement to provide the corresponding quinolone-phenol in high yield.